Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Calcipotriene/Betamethasone vs Taclonex in Scalp Psoriasis
NCT03331523Phase 3Completed
- Sponsor
- Glenmark Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of calcipotriol + betamethasone in psoriasis (3 arms), sponsored by Glenmark Pharmaceuticals. Primary endpoints: Proportion of subjects with treatment success on the PGA scale at Day 29 and Proportion of subjects with clinical success on the PASI scale at Day 29. Started Oct 2017; status: completed.
02
Drugs
calcipotriol + betamethasone
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03331523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331523.